Internal Medicine Journal · 2020 · 54 citations · 19 references
MedicineCardiologySurgeryCardiothoracic SurgeryHemodynamic ManagementPulmonologyHypertension ManagementPrognostic AssessmentPulmonary HypertensionPulmonary Vascular DiseaseFunctional Class AssessmentIdiopathic Pulmonary HypertensionPortopulmonary HypertensionPrognostic Factors Analysis
BACKGROUND: Portopulmonary hypertension (PoPH) is a rare condition with poorer survival compared to idiopathic/familial pulmonary arterial hypertension (IPAH/FPAH). AIMS: To compare the characteristics, survival, prognostic factors and management of PoPH and IPAH/FPAH patients and to assess the impact of treatment on survival of PoPH patients. METHODS: Analysis of data of prevalent and incident PoPH patients enrolled in the Spanish registry of PAH (REHAP) from January 1998 to December 2017 and comparison with IPAH/FPAH patients. Variables analysed: patient and disease (PAH and liver) characteristics, first-line PAH-targeted therapy, causes of death, prognostic factors and survival (according to aetiology and treatment in PoPH patients). RESULTS: Compared to IPAH/FPAH patients (n = 678), patients with PoPH (n = 237) were predominantly men, older and had better functional class and higher prevalence of ascites. Haemodynamics were better. Biomarkers for heart failure were worse. Age- and sex-adjusted 5-year survival rate from diagnosis was 49.3% for PoPH patients and 68.7% for IPAH patients (P < 0.001). Treated PoPH had better survival than non-treated. PAH- and liver-related causes accounted for 30.2% and 24.7% of deaths in PoPH patients. PoPH patients were less likely to receive first-line PAH-targeted therapy and this was associated with greater mortality. Increasing age, worse exercise capacity and ascites were independent prognostic factors of poorer survival; first-line oral monotherapy was associated with improved survival. Eight (3.4%) PoPH patients underwent liver transplantation. CONCLUSIONS: PoPH patients are undertreated and show poorer survival than IPAH/FPAH patients. First-line treatment with PAH-targeted therapy was associated with better survival. Presence of ascites was a predictor of mortality.
19
Nazzareno Galiè, Marius M. Hoeper, Marc Humbert et al. · European Heart Journal · 2009 · 3.9K citations · Full text
Pulmonary Arterial Hypertension in France
Marc Humbert, Olivier Sitbon, Ari Chaouat et al. · American Journal of Respiratory and Critical Care Medicine · 2006 · 2K citations
Pulmonary Arterial Hypertension
David B. Badesch, Gary E. Raskob, C. Gregory Elliott et al. · CHEST Journal · 2009 · 1.2K citations